What is ClinDatrix?
ClinDatrix operates as a contract research organization (CRO) catering to the pharmaceutical, biotechnology, and medical device industries worldwide. The company distinguishes itself by offering world-class performance and quality at a moderate price point, positioning it as a competitive player in the global CRO market. Its services are crucial for clients navigating the complex landscape of drug development and medical device innovation.
How much funding has ClinDatrix raised?
ClinDatrix has raised a total of $898K across 4 funding rounds:
Debt
$150K
Debt
$98K
Debt
$150K
Debt
$500K
Debt (2020): $150K with participation from PPP
Debt (2021): $98K led by PPP
Debt (2024): $150K, investors not publicly disclosed
Debt (2024): $500K featuring Northeast Bank
Key Investors in ClinDatrix
Northeast Bank
Northeast Bank is a financial institution that has provided debt financing to ClinDatrix, indicating a role in supporting the company's operational and growth capital needs.
PPP
Public-Private Partnership
What's next for ClinDatrix?
The recent major enterprise-level funding and strategic investment signal a pivotal moment for ClinDatrix. This influx of capital is likely to fuel further expansion of its service offerings, enhancement of its technological infrastructure, and broader market penetration. The company is poised to leverage this financial backing to solidify its position as a leading CRO, potentially exploring new therapeutic areas or geographical markets to drive sustained growth and innovation in clinical research.
See full ClinDatrix company page
